# US 2008/0187511 A1 · Ointment for cancer treatment

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0187511 A1
- Document ID: US20080187511A1
- Status: Published application
- Kind: A1
- Application number: 11/924,354
- Filed: 2007-10-25
- Published: 2008-08-07
- Earliest claimed: 2006-10-25
- Assignees: University of Pittsburgh - Of the Commonwealth; System of Higher Education
- Inventors: Michael R. Shurin; Valerian E. Kagan; Galina V. Shurin; Yulia Tyurina
- Web page: https://patentgrep.com/patent/US20080187511A1

## CPC

- A61K 31/685: one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention provides an oil-based pharmaceutical composition comprising as an active ingredient phostphatidylserine or a derivative thereof and a pharmaceutically acceptable oil-based carrier, which is formulated for topical or intratumoral administration. Preferably, the composition is an ointment or a cream. The composition can contain additional active agents as well, such as aminophospholipid translocase inhibitors, transnitrosylating agents, chemokines, cytokines, Toll-like receptor ligands, imidazoquinolines, dendritic cell differentiation factors, or combinations thereof. In another aspect, the invention provides a method of treating cancer within a patient in need of treatment by administering the inventive composition to the patient.

## Claims

### Claim 1

A pharmaceutical composition comprising as an active ingredient phosphatidylserine (PS) or a derivative thereof and a pharmaceutically acceptable oil-based carrier, wherein the composition is formulated for topical administration.

### Claim 2 (depends on 1)

The composition of claim 1, which is an ointment or a cream.

### Claim 3 (depends on 1)

The composition of claim 1, wherein a derivative of PS comprises two saturated fatty acids, saturated and monounsaturated (oleic, C18:1), or polyunsaturated fatty acids (linoleic C18:2, linolenic C18:3, arachidonic C20:4, docosahexaenoic C20:4) or lyso-forms of such fatty acids.

### Claim 4 (depends on 1)

The composition of claim 1, wherein a derivative of PS is an oxidized form of PS or a lyso-form of such oxidized derivative.

### Claim 5 (depends on 1)

The composition of claim 1, wherein the PS or a derivative thereof is present in a concentration of from about 1 wt % to about 20 wt % of the composition.

### Claim 6 (depends on 1)

The composition of claim 1, wherein the carrier comprises phosphatidylcholine or a derivative thereof.

### Claim 7 (depends on 1)

The composition of claim 1, wherein the carrier comprises a fatty acid, a polyunsaturated fatty acid, or a combination thereof.

### Claim 8 (depends on 7)

The composition of claim 7, wherein the carrier comprises oleic acid (C18:1), linoleic acid (C18:2), linolenic acid (C18:3), or a combination thereof.

### Claim 9 (depends on 1)

The composition of claim 1, comprising an aminophospholipid translocase inhibitor.

### Claim 10 (depends on 9)

The composition of claim 9, wherein the aminophospholipid transolcase inhibitor is selected from the group consisting of N-ethyl-maleimide and pyridyldithioethylamine.

### Claim 11 (depends on 1)

The composition of claim 1, comprising a transnitrosylating agent.

### Claim 12 (depends on 11)

The composition of claim 11, wherein the transnitrosylating agent is S-nitro-glutathione or S-nitro-cysteine-N-ethyl ether.

### Claim 13 (depends on 1)

The composition of claim 1, comprising an imidazoquinoline.

### Claim 14 (depends on 13)

The composition of claim 13, wherein the imidazoquinolin is amiquimod (1-[2-methylpropyl]-1H-imidazo[4,5c]quinoline-4-amine), resiquimod (4-amino-α,α-dimethyl-2-ethoxylmethyl-1H-imidazo[4,5-c]-quinoline-1-ethanol), or a combination thereof.

### Claim 15 (depends on 13)

The composition of claim 13, wherein the imidazoquinolin comprises from about 1 wt % to about 10 wt % of the composition.

### Claim 16 (depends on 1)

The composition of claim 1, comprising an immune response modifier.

### Claim 17 (depends on 16)

The composition of claim 16, wherein an immune response modifier is selected from the group consisting of chemokines, cytokines, Toll-like receptor ligands, dendritic cell differentiation factors, or a combination thereof.

### Claim 18 (depends on 17)

The composition of claim 17, wherein an immune response modifier comprises a chemokine and is present in the composition at a concentration of between about 1 ng/g to 1 mg/g.

### Claim 19 (depends on 17)

The composition of claim 17, wherein an immune response modifier comprises a cytokine and is present in the composition at a concentration of between about 1 ng/g to 1 mg/g.

### Claim 20 (depends on 17)

The composition of claim 17, wherein the immune response modifier comprises a Toll-like receptor ligands that activate dendritic cells.

### Claim 21 (depends on 20)

The composition of claim 20, wherein a Toll-like receptor ligand lacks direct effects on tumor cells.

### Claim 22 (depends on 20)

The composition of claim 20, wherein the Toll-like receptor ligand is present at a concentration at between about 1 μg/g and about 50 mg/g.

### Claim 23 (depends on 17)

The composition of claim 17, wherein an immune response modifier comprises a dendritic cell differentiating factor.

### Claim 24 (depends on 23)

The composition of claim 23, wherein the dendritic cell differentiating factor is present in the composition at a concentration of between about 1 μg/g and about 1 mg/g.

### Claim 25

A method of treating a neoplastic disorder in a human patient comprising topically applying to the human patient a pharmaceutical composition in an amount and at a location sufficient to treat the neoplastic disorder within the human patient, the composition comprising as an active ingredient phosphatidylserine (PS) or a derivative thereof and a pharmaceutically acceptable oil-based carrier and wherein the neoplastic disorder is oral cancer, rectal cancer, head and neck cancer, epithelial cancer, melanoma, basal cell carcinoma, squamous cell carcinoma, or lymphoma.

### Claim 26 (depends on 25)

The method of claim 25, wherein the composition is an ointment or a cream.

### Claim 27 (depends on 25)

The method of claim 25, wherein the derivative of PS comprises two saturated fatty acids, saturated and monounsaturated (oleic, C18:1), or polyunsaturated fatty acids (linoleic C18:2, linolenic C18:3, arachidonic C20:4, docosahexaenoic C20:4) or lyso-forms of such fatty acids.

### Claim 28 (depends on 25)

The method of claim 25, wherein the derivative of PS is an oxidized form of PS or a lyso-form of such oxidized derivative.

### Claim 29 (depends on 25)

The method of claim 25, wherein the PS or a derivative thereof is present in a concentration of from about 1 wt % to about 20 wt % of the composition.

### Claim 30 (depends on 25)

The method of claim 25, wherein the composition is applied to deliver PS or a derivative thereof in a dosage between about 10 μg/cm2/day and about 75 μg/cm2/day.

### Claim 31 (depends on 25)

The method of claim 25, wherein the carrier comprises phosphatidylcholine or a derivative thereof.

### Claim 32 (depends on 25)

The method of claim 25, wherein the carrier comprises a fatty acid, a polyunsaturated fatty acid, or a combination thereof.

### Claim 33 (depends on 32)

The method of claim 32, wherein the carrier comprises oleic acid (C18:1), linoleic acid (C18:2), linolenic acid (C18:3), or a combination thereof.

### Claim 34 (depends on 25)

The method of claim 25, wherein the composition comprises an aminophospholipid translocase inhibitor.

### Claim 35 (depends on 34)

The method of claim 34, wherein the aminophospholipid transolcase inhibitor is selected from the group consisting of N-ethyl-maleimide and pyridyldithioethylamine.

### Claim 36 (depends on 25)

The method of claim 25, wherein the composition comprises a transnitrosylating agent.

### Claim 37 (depends on 36)

The method of claim 36, wherein the transnitrosylating agent is S-nitro-glutathione or S-nitro-cysteine-N-ethyl ether.

### Claim 38 (depends on 25)

The method of claim 25, wherein the composition comprises an imidazoquinoline.

### Claim 39 (depends on 28)

The method of claim 28, wherein the imidazoquinolin is amiquimod (1-[2-methylpropyl]-1H-imidazo[4,5c]quinoline-4-amine), resiquimod (4-amino-α,α-dimethyl-2-ethoxylmethyl-1H-imidazo[4,5-c]-quinoline-1-ethanol), or a combination thereof.

### Claim 40 (depends on 38)

The method of claim 38, wherein the imidazoquinolin comprises from about 1 wt % to about 10 wt % of the composition.

### Claim 41 (depends on 25)

The method of claim 25, wherein the composition comprises an immune response modifier.

### Claim 42 (depends on 41)

The method of claim 41, wherein an immune response modifier is selected from the group consisting of chemokines, cytokines, Toll-like receptor ligands, dendritic cell differentiation factors, or a combination thereof.

### Claim 43 (depends on 42)

The method of claim 42, wherein an immune response modifier comprises a chemokine and is present in the composition at a concentration of between about 1 ng/g to 11 mg/g.

### Claim 44 (depends on 42)

The method of claim 42, wherein an immune response modifier comprises a cytokine and is present in the composition at a concentration of between about 1 ng/g to 1, mg/g.

### Claim 45 (depends on 42)

The method of claim 42, wherein the immune response modifier comprises a Toll-like receptor ligand that activates dendritic cells.

### Claim 46 (depends on 45)

The method of claim 45, wherein a Toll-like receptor ligand lacks direct effects on tumor cells.

### Claim 47 (depends on 45)

The method of claim 45, wherein the Toll-like receptor ligand is present at a concentration at between about 1 μg/g and about 50 mg/g.

### Claim 48 (depends on 42)

The method of claim 42, wherein an immune response modifier comprises a dendritic cell differentiating factor.

### Claim 49 (depends on 48)

The method of claim 48, wherein the dendritic cell differentiating factor is present in the composition at a concentration of between about 1 μg/g and about 1 mg/g.
